Selumetinib and Azacitidine in High Risk Chronic Blood Cancers

NCT03326310 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Chronic Myeloid Leukemia
Myelofibroses

Interventions

DRUG: Azacitidine
DRUG: Selumetinib

Sponsor

University of Chicago